Advertisement
Round 2: No win for the ACA

Round 2: No win for the ACA

By Merrill Goozner  |  February 14, 2015

Forget the smiley face the administration will put on the final numbers from the Affordable Care Act open-enrollment season that just ended. Sign-ups are lagging far behind original projections. And with the political and legal landscape littered with landmines, it's not going to get any easier.

What would Cotton Mather say about the measles vaccine?

What would Cotton Mather say about the measles vaccine?

By Merrill Goozner  |  February 07, 2015

Despite the extraordinary gains in public health brought about by vaccinations, there has never been a shortage of people who balk at the scientifically proven method for preventing infectious disease.

Beware vaporware on value-based care

Beware vaporware on value-based care

By Merrill Goozner  |  January 31, 2015

The dictionary defines vaporware as a product that has been widely advertised but has not and may never become available. Last week's twin announcements on the imminent move to widespread value-based reimbursement in healthcare bring the concept to mind.

Boosting the right kind of innovation

Boosting the right kind of innovation

By Merrill Goozner  |  January 24, 2015

Nearly two decades ago, Harvard Business School professor Clayton Christensen coined the phrase “disruptive innovation” to describe new technologies that transform industries by bringing simplicity and affordability to products and processes that are complicated and high cost.

National action needed to advance telemedicine

National action needed to advance telemedicine

By Merrill Goozner  |  January 17, 2015

Telehealth, which has been around for four decades, lives in regulatory limbo, despite being one of the more promising technologies for improving patient outcomes and lowering costs.

Why the FDA should regulate lab tests

Why the FDA should regulate lab tests

By Merrill Goozner  |  January 10, 2015

The Food and Drug Administration's proposal to regulate the accuracy of laboratory-developed tests has drawn heated opposition from the laboratory testing industry, hospitals and most medical specialty societies. Only oncologists favor tighter oversight.

Lessons from Vermont

Lessons from Vermont

By Merrill Goozner  |  January 03, 2015

Sorting through the shards of Vermont's discarded single-payer health insurance scheme reveals the plan was undone by its generosity toward patients, hospitals and physicians, not its core assumptions.

A holiday wish list for healthcare

A holiday wish list for healthcare

By Merrill Goozner  |  December 20, 2014

The holiday season is a time when we count our blessings and shower gifts on those we love. It's also the time when we vow to do better in the coming year.

10 reasons why healthcare isn't a free market

10 reasons why healthcare isn't a free market

By Merrill Goozner  |  December 13, 2014

Before the mass resignations at The New Republic, one of the new executives hired by its 31-year-old sugar-daddy owner reportedly asked for a "listicle" on “10 reasons why healthcare isn't a free market.” He didn't get it, but what a great idea.

The $2.6 billion pill

The $2.6 billion pill

By Merrill Goozner  |  November 29, 2014

That's the updated estimate of the cost to develop a new drug from the Tufts Center for the Study of Drug Development. Anyone with even a rudimentary understanding of corporate accounting knows the claim is bogus.

Advertisement
Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.